Clinical Trial Update: Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CERE-120 for Parkinson's disease reports completed Phase 1/2 results with data posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CERE-120

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Idiopathic Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-26